Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington. Show more

Location: 107 Spring Street, Seattle, WA, 98104, United States | Website: https://www.atossatherapeutics.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

103.2M

52 Wk Range

$0.55 - $1.30

Previous Close

$0.80

Open

$0.82

Volume

299,225

Day Range

$0.77 - $0.82

Enterprise Value

51.4M

Cash

51.85M

Avg Qtr Burn

-6.569M

Insider Ownership

0.07%

Institutional Own.

19.45%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
(Z)-Endoxifen (Estrogen Modulator) Details Metastatic Breast Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
(Z)-endoxifen Details Ductal Carcinoma In Situ	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
(Z)-endoxifen + Abemaciclib (VERZENIO®) Details Breast cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AT-301 Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AT-H201 Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.